FOLH1 and prostate cancer: Despite the high diagnostic performance of PET/CT with 68Ga-labeled PSMA radiotracers in patients with BCR of prostate cancer, a considerable proportion of negative findings has also been reported, particularly in patients with low PSA levels [11–14].